These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38042867)

  • 1. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
    Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
    Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH; Ismail NF; Zabidi-Hussin Z
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH; Kademane K; Chai Soon Hou S; Jocelyn TXY; Zabidi-Hussin Z
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011272. PubMed ID: 37432030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
    Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
    Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
    Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
    PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
    Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
    J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.